The steady increase in stocks shifting into long-term bear market trends has implications for the broader market as we head into 2025. The negative momentum that is building is likely to create a ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $176.92, representing a 20.98% upside. In a report released on December 11, Citi also maintained ...

With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However, stock ...

BofA Securities has recently resumed Johnson & Johnson (JNJ) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

Shares of Johnson & Johnson JNJ slid 0.27% to $146.24 Thursday, on what proved to be an all-around rough trading session for ...

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

When asked about Advanced Micro Devices, Cramer asks: "But can we just remember Lisa Su has built an amazing company?" ...

This was the stock's second consecutive day of losses.

Johnson & Johnson (JNJ) stock saw a decline, ending the day at $149.23 which represents a decrease of $-0.37 or -0.25% from the prior close of $149.6. The stock opened at $149.93 and touched a low of ...

The valuation of Elon Musk’s SpaceX hit $350 billion based on a secondary share sale, CNBC confirmed Wednesday.